Shares of Exelixis Inc. (EXEL) are rising over 13% in pre-market today, after the company announced its partner Takeda Pharma received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma or RCC.
from RTT - Before the Bell https://ift.tt/3bBgJDd
via IFTTT
No comments:
Post a Comment